Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

Trading Statement

23 Jan 2012 07:01

RNS Number : 9672V
Surgical Innovations Group PLC
23 January 2012
 



For immediate release

23 January 2012

 

 

Surgical Innovations Group plc

("SI" or "the Group")

Trading update

 

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery, is pleased to provide the following trading update.

 

During the year to 31 December 2011 the Group has traded in line with market expectations.

 

In difficult market conditions SI continued to trade according to plan in the second half of 2011, with a strong fourth quarter. The focus towards development of US opportunities is a major element of the company's strategy, particularly with the current challenges throughout the European market. Orders from the US have continued to grow as a result of strengthened routes to market complementing our Master Dealer's growing distribution network.

 

The Group has continued to see positive results from its investment program in product development; sales of the innovative PretzelFlex™ laparoscopic retractor have been encouraging following its launch in November. In addition, new handle technology with improved ergonomics for an OEM customer will soon be undergoing clinical evaluations in preparation for launch in the US market.

 

The concept and development teams have benefited from support from our Clinical Advisory Board, which has been strengthened by three new appointments this month from the fields of general surgery and arthroscopy. We have made advances with our arthroscopy project, and the Group is targeted to introduce a number of new pre-production products at an international arthroscopic clinical congress in the second half of 2012.

 

The senior management and finance team was strengthened following the appointment of Mike Thornton, formerly a partner at PricewaterhouseCoopers, as Financial Director of Surgical Innovations Limited in December. Mike, who reports directly to Graham Bowland and the Group Board, has already made a positive impact.

 

Graham Bowland, Chief Executive Officer, said: "SI has made progress in 2011, particularly in the US and in the development and launch of new products. The Group looks forward with confidence."

 

Preliminary results for the year to 31 December 2011 are expected to be released on 24 April 2012.

- Ends -

For further enquiries:

Surgical Innovations Group plcDoug Liversidge, ChairmanGraham Bowland, Chief Executive Officer +44 (0)113 230 7597

Seymour Pierce Limited

Freddy Crossley/ Sarah Jacobs Tel: +44 (0) 20 7107 8000

Corporate Broking

David Banks / Jacqui Briscoe www.seymourpierce.com

The Communications PortfolioAriane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

 

 

Notes to Editors:

About Surgical Innovations Group plc

Surgical Innovations Group plc specialises in the design and manufacture of innovative devices for use in minimally invasive surgery (MIS) and industrial markets.

As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.

Over 140 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.

The Group's patented products are sold through three main channels:

SI brand

Through an established network of 45 distribution partners, Surgical Innovations branded products are sold in all major medical markets including North America, Europe, South Africa, the Middle East, South-east Asia and Australia.

OEM and IP

The Group supplies large medical device companies on an OEM basis, collecting both sales and IP royalty fees. Clients include Teleflex Medical, Olympus, Gyrus and CareFusion.

Industrial

 

SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, in situ with minimum disassembly and downtime.

For more information, see www.sigroupplc.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGMGZMRZDGZZM
Date   Source Headline
27th Jun 20223:15 pmRNSResult of AGM
27th Jun 20227:00 amRNSAGM Trading Statement
25th May 20227:00 amRNSPosting of 2021 Annual Report & Accounts
9th May 202212:41 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSFinal Results
21st Mar 20227:00 amRNSProduct launch in partnership with CMR Surgical
10th Mar 20227:00 amRNSNotice of Annual Results
17th Jan 20227:00 amRNSYear-end Trading Update
15th Nov 20217:00 amRNSChanges to Board Structure & CFO Appointment
10th Nov 20215:43 pmRNSGrant of Options
15th Sep 20217:00 amRNSHalf-year Report
27th Aug 20217:00 amRNSNotice of Interim Results
9th Jul 20212:29 pmRNSDirector/PDMR Shareholding
22nd Jun 20215:26 pmRNSResult of AGM
22nd Jun 20217:00 amRNSAGM Trading Statement
21st Jun 20217:00 amRNSWithdrawal of AGM Resolution
21st May 20217:00 amRNSPosting of Annual Report& Accounts & Notice of AGM
25th Mar 20217:00 amRNSFinal Results
22nd Mar 20217:00 amRNS3-year Exclusive UK distribution agreement
8th Mar 20217:00 amRNSNotice of annual results
15th Feb 20217:00 amRNS5-year USA distribution agreement
9th Feb 20217:00 amRNSLaunch of the Green Surgery Challenge
8th Jan 20217:00 amRNSDistalmotion’s Dexter Robot receives CE Mark
7th Jan 20217:00 amRNSFuture board change
21st Dec 20207:00 amRNSTrading update
17th Dec 20207:00 amRNSUS distribution agreement signed with Adler
7th Dec 20203:00 pmRNSReplacement of Auditor
2nd Dec 20207:00 amRNSProduct launch for Cellis Breast
25th Nov 20207:00 amRNSCentre for Sustainable Healthcare collaboration
25th Sep 202011:50 amRNSHolding(s) in Company
23rd Sep 20205:20 pmRNSHolding(s) in Company
21st Sep 20201:46 pmRNSHolding(s) in Company
18th Sep 20204:08 pmRNSResult of AGM
17th Sep 202012:54 pmRNSResult of Fundraise
17th Sep 20207:01 amRNSProposed Fundraise
8th Sep 20207:00 amRNSHalf-year Report
21st Aug 20207:00 amRNSNotice of results and Change of AGM 2020 Date
10th Aug 20205:57 pmRNSHolding(s) in Company
10th Jun 20207:00 amRNSPostponement of the Annual General Meeting 2020
4th Jun 20204:50 pmRNSDirector/PDMR Shareholding
4th Jun 20207:00 amRNSNHS Sustainability Webinar
28th May 20207:00 amRNSUpdate on trading &extension to banking facilities
31st Mar 20207:00 amRNSFinal Results
27th Mar 20203:05 pmRNSNotice of results and trading update
13th Jan 20207:00 amRNSYear-end Trading Update
11th Nov 20196:09 pmRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSDirector/PDMR Shareholding
5th Nov 20192:56 pmRNSDirector/PDMR Shareholding
25th Oct 20193:12 pmRNSDirector/PDMR Shareholding
7th Oct 20194:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.